Merck Sells $2 Billion of Bonds After Upgrade by S&P

Merck & Co., the second-largest U.S. drugmaker, sold $2 billion of senior unsecured bonds to repay debt coming due next year, an offering that came within two weeks of Standard & Poor’s raising its rating on the company.

Bank of America Corp. and JPMorgan Chase & Co. managed the transaction, which included $850 million of 5-year notes and $1.15 billion of 10-year debt, according to data compiled by Bloomberg.

S&P raised the drugmaker’s rating one level to AA on Nov. 24, citing Merck’s faster-than-expected debt reduction after buying Schering-Plough Corp. last year. Proceeds will be used for general corporate purposes, including cutting short-term debt, Whitehouse Station, New Jersey-based Merck said in the filing.

“Merck probably isn’t going to save a lot in interest expense by refinancing its short-term debt, but it’s still a good idea to address those maturities now while the bond market continues to be welcoming,” said Carol Levenson, director of research at Gimme Credit LLC in Chicago, said in an e-mail.

“Taking advantage of the recent upgrade is also a good idea,” she said.

The 5-year, 2.25 percent notes yield 57 basis points more than similar-maturity Treasuries, and the 10-year, 3.875 percent debt pays a spread of about 77 basis points, Bloomberg data show. A basis point is 0.01 percentage point.

‘High Standing’

Moody’s Investors Service assigned Merck’s notes a grade of A1, one step lower than S&P. Merck benefits from “a relatively high standing in credit markets, with ready access to capital,” S&P said in its Nov. 24 statement.

The pharmaceuticals maker had $4.1 billion of debt due in the 12 months ending Sept. 30, 2011, it said in today’s filing.

Merck last sold bonds in June 2009, when it raised $4.25 billion in a four-part offering, its largest ever, to help pay for the Schering-Plough takeover, according to data compiled by Bloomberg.

Pfizer Inc., based in New York, is the world’s largest drugmaker.

To contact the reporter on this story: Tim Catts in New York at tcatts1@bloomberg.net.

To contact the editor responsible for this story: Alan Goldstein at agoldstein5@bloomberg.net.

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.